(Q38165714)

30 August 2017

Discovery and development of first in class antifungal caspofungin (CANCIDAS®)--a case study (English)

1 reference

30 August 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

131609

(10R,12S)-caspofungin

1 reference

ChEBI release 2020-05-28

James M Balkovec

1

1 reference

30 August 2017

David L Hughes

2

1 reference

30 August 2017

Prakash S Masurekar

3

1 reference

30 August 2017

Carole A Sable

4

1 reference

30 August 2017

Robert E Schwartz

5

1 reference

30 August 2017

Sheo B Singh

6

1 reference

30 August 2017

1 January 2014

1 reference

30 August 2017

Natural Product Reports

1 reference

30 August 2017

31

1 reference

30 August 2017

1

1 reference

30 August 2017

15-34

1 reference

Treatment of systemic fungal infections: recent progress and current problems

30 August 2017

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Glucan synthase inhibitors as antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Isolation and expression of the Pneumocystis carinii thymidylate synthase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Determination of the relative and absolute configuration of the dimethylmyristoyl side chain of pneumocandin B0 by asymmetric synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Changes in serum enzyme levels following ketamine infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Influence of mobile phase composition and thermodynamics on the normal phase chromatography of echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Fungal infections in cancer patients: an international autopsy survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Invasive aspergillosis in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC3NP70070D

Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.45.1886

Studies on aculeacin. I. Isolation and characterization of aculeacin A

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.30.297

Mulundocandin, a new lipopeptide antibiotic. I. Taxonomy, fermentation, isolation and characterization

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.40.275

Identifiers

DOI

10.1039/C3NP70070D

1 reference

30 August 2017

1 reference